Market Overview

UPDATE: Piper Jaffray Raises PT to $118 on Edwards Lifesciences on Lower Risks Ahead

Related EW
Edwards Receives FDA Clearance For Advanced Noninvasive Monitoring System
Edwards Lifesciences' Sapien XT Gains Approval, Competition Rife - Analyst Blog

Piper Jaffray reiterated its Overweight rating on Edwards Lifesciences (NYSE: EW) and increased its price target on shares from $90 to $118 in a research report published Friday.

Piper Jaffray noted, "We are raising our price target on EW reflecting the reduction in risk inherent with the positive national coverage decision (NCD), positive FDA panel meeting on high-risk patients, and the removal of uncertainty related to the outcome of the Supreme Court decision on the Affordable Care Act (ACA)."

Edwards Lifescience closed at $104.44 on Thursday.

Posted-In: Piper JaffrayAnalyst Color Price Target Reiteration Pre-Market Outlook Analyst Ratings

 

Most Popular

Related Articles (EW)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free